Forest To Review Role In Desmoteplase Program Following DIAS-2 Failure
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Development of Forest/Paion's clot dissolving protein desmoteplase for the treatment of acute ischemic stroke could be in question after a Phase III study failed to show an efficacy benefit in patients treated with the drug versus placebo
You may also be interested in...
Forest/PAION Desmoteplase Scare Is Brief: Trial Resumes After Two-Day Hold
A pre-Halloween scare for PAION/Forest's vampire bat protein-based stroke therapy desmoteplase resolved quickly when a halt on patient recruitment in a Phase IIb/III trial was lifted within two days of the announcement of a possible safety signal
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.